Both companies may succeed in this industry.

Eli Lilly stock has been climbing back from a recent pullback and nearing a buy point. The drugmaker teamed up with Nvidia on ...

Eli Lilly looks undervalued as earnings forecasts rise and GLP-1 catalysts near. Read the full analysis here of LLY stock.

Eli Lilly is Wednesday's IBD Stock Of The Day. Lilly shares are bounding off their 50-day line with a new buying opportunity ...

This biotech has candidates in late-stage clinical development.

This drugmaker continues to strengthen its investment thesis.

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive ...

The company got some bad news to start 2026.

Eli Lilly is tackling a high-growth market: weight loss. The company’s weight loss portfolio brought in $10 billion in the ...

Eli Lilly and Co (NYSE: LLY) has outperformed the market over the past 5 years by 25.43% on an annualized basis producing an ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and ...

After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition ...